Actively Recruiting

Phase 3
Age: 18Years +
FEMALE
NCT06033131

PI4 - A Trial Assessing Metformin to Prolong Gestation in Preterm Preeclampsia

Led by Lina Bergman · Updated on 2026-05-04

294

Participants Needed

17

Research Sites

310 weeks

Total Duration

On this page

Sponsors

L

Lina Bergman

Lead Sponsor

T

The Swedish Research Council

Collaborating Sponsor

AI-Summary

What this Trial Is About

Preterm preeclampsia is a severe condition for both the mother and the fetus. Currently, the only treatment available to stop disease progression is termination/delivery of the fetus and placenta. Therefore, preterm preeclampsia carries the highest rates of neonatal morbidity and mortality due to iatrogenic preterm birth. There is evidence suggesting metformin, a drug commonly used to treat diabetes in and outside pregnancy, may be able to counter the pathophysiology of preeclampsia, raising the possibility that it could be used to treat the condition. This multi centre double blind randomised controlled trial aims to investigate if metformin can prolong gestation, lower neonatal length of stay and increase birthweight in a Nordic setting.

CONDITIONS

Official Title

PI4 - A Trial Assessing Metformin to Prolong Gestation in Preterm Preeclampsia

Who Can Participate

Age: 18Years +
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosed with preeclampsia confirmed by hypertension and significant proteinuria
  • Planning to manage preeclampsia expectantly as assessed by clinicians
  • Provided written consent to participate
  • Female aged 18 years or older
  • Gestational age between 22+0 and 33+6 weeks with a viable single fetus
  • Carrying a singleton pregnancy
Not Eligible

You will not qualify if you...

  • Any contraindications to metformin treatment
  • Immediate need for delivery according to preeclampsia guidelines
  • Diagnosis of Type 1 Diabetes Mellitus
  • Current metformin use
  • Known or suspected allergy to metformin
  • Difficulty understanding study participation due to language or other issues
  • Unable to provide informed consent
  • Previous participation in this study
  • Fetal compromise requiring imminent delivery
  • Suspicion of major fetal anomaly or malformation
  • Renal disease indicated by creatinine ≥125 µmol/L or rapidly declining function
  • Known acute or chronic metabolic acidosis including diabetic ketoacidosis
  • Deemed unsuitable for inclusion by the investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 17 locations

1

Helsinki University Hospital

Helsinki, Finland, 00290

Not Yet Recruiting

2

Tampere University Hospital

Tampere, Finland, 33520

Actively Recruiting

3

Akershus University Hospital

Lørenskog, Norway, N-1474

Not Yet Recruiting

4

Oslo University Hospital

Oslo, Norway, 0372

Not Yet Recruiting

5

Södra Älvsborgs Hospital

Borås, Sweden, 50455

Actively Recruiting

6

Falu Lasarett

Falun, Sweden, 79129

Actively Recruiting

7

Sahlgrenska University Hospital

Gothenburg, Sweden, 416 85

Actively Recruiting

8

Linköping University Hospital

Linköping, Sweden, 581 85

Actively Recruiting

9

Skåne University Hospital

Lund, Sweden, 221 85

Actively Recruiting

10

Skåne University Hospital

Malmö, Sweden, 205 02

Actively Recruiting

11

Karolinska University Hospital Huddinge

Stockholm, Sweden, 14157

Actively Recruiting

12

Karolinska University Hospital Solna

Stockholm, Sweden, 17176

Actively Recruiting

13

Danderyd Hospital

Stockholm, Sweden, 182 88

Actively Recruiting

14

Norra Älvsborgs County Hospital

Trollhättan, Sweden, 461 74

Actively Recruiting

15

Norrland´s University Hospital

Umeå, Sweden, 901 85

Actively Recruiting

16

Uppsala University Hospital

Uppsala, Sweden, 75237

Actively Recruiting

17

Västmanlands Hospital Västerås

Västerås, Sweden, 72335

Not Yet Recruiting

Loading map...

Research Team

L

Lina Bergman, Associate Professor

CONTACT

P

Pia Gudmundsson, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here